The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.

中文翻译：

---

局部 CAR T 细胞疗法：实体瘤系统免疫的点火钥匙

与血液系统恶性肿瘤不同，嵌合抗原受体 (CAR) T 细胞疗法在实体瘤中的成功受到肿瘤浸润不足以及 T 细胞功能障碍和耗竭的限制。CAR T细胞在实体瘤患者中的区域递送是安全可行的；促进渗透、扩散和贩运；并激发功能持久的系统免疫。